A 2a adenosine receptor antagonists

Details A 2a adenosine receptor antagonists A 2a adenosine receptor antagonists

2004-04-09

2010-11-16

Balasubramanian, Venkataraman (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S207000, C544S209000, C544S212000

Reexamination Certificate

active

07834014

ABSTRACT:
The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2aadenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula (I).

REFERENCES:
patent: 4739053 (1988-04-01), Albert et al.
patent: 5204353 (1993-04-01), Meier
patent: 5356894 (1994-10-01), Rodney et al.
patent: 5458135 (1995-10-01), Patten et al.
patent: 5747496 (1998-05-01), Cox et al.
patent: 6005109 (1999-12-01), Faraci et al.
patent: 6107301 (2000-08-01), Aldrich et al.
patent: 6197788 (2001-03-01), Fletcher et al.
patent: 6583156 (2003-06-01), Gillespie et al.
patent: 6608085 (2003-08-01), Gillespie et al.
patent: 6787541 (2004-09-01), Gillespie et al.
patent: 7285550 (2007-10-01), Vu et al.
patent: 0390112 (1990-10-01), None
patent: 0459702 (1991-12-01), None
patent: 0496617 (1992-07-01), None
patent: 0515107 (1992-11-01), None
patent: 0666079 (1995-08-01), None
patent: 0667349 (1995-08-01), None
patent: 0976753 (2000-02-01), None
patent: 0976755 (2000-02-01), None
patent: 0992510 (2000-04-01), None
patent: 1221444 (2001-01-01), None
patent: 1116722 (2001-07-01), None
patent: 1300147 (2003-04-01), None
patent: 223066 (1974-05-01), None
patent: 56131586 (1981-10-01), None
patent: 56131587 (1981-10-01), None
patent: 59062595 (1984-04-01), None
patent: 60140335 (1985-07-01), None
patent: 04036284 (1992-02-01), None
patent: WO9320078 (1993-10-01), None
patent: WO9413643 (1994-06-01), None
patent: WO9413677 (1994-06-01), None
patent: WO9417803 (1994-08-01), None
patent: WO9713676 (1997-04-01), None
patent: WO9901439 (1999-01-01), None
patent: WO9901454 (1999-01-01), None
patent: WO9943678 (1999-02-01), None
patent: WO9921617 (1999-05-01), None
patent: WO9940091 (1999-08-01), None
patent: WO9948903 (1999-09-01), None
patent: WO9962518 (1999-12-01), None
patent: WO0017201 (2000-03-01), None
patent: WO0061586 (2000-10-01), None
patent: WO0102400 (2001-01-01), None
patent: WO0102409 (2001-01-01), None
patent: WO0162233 (2001-08-01), None
patent: WO03020723 (2003-03-01), None
patent: WO03048163 (2003-06-01), None
patent: WO03068776 (2003-08-01), None
patent: WO2004029056 (2004-04-01), None
Baraldi et al., European Journal of Medicinal Chemistry 38: 367-382, 2003.
Koretskaya et al., Khim.-Farm. Zh. I (1968) 2(6) 5-12.
Mamaev et al., Getertsikl, Soedin, (1971) 7, 535.
Pendergast et al., J. Chem. Soc. Perkin. Trans. (1973) 1, 2759-2763.
Machon et al., J. Pharmacol. Pharm. (1976) 28, 511.
Higashino et al., Chem Pharm Bull 24, 238-52 (1976).
Higashino et al., Chem Pharm Bull 24, 3120-34 (1976).
Hayashi et al., Yakugaku Zasshi 98, 891 (1978) Abstract.
Robev et al., Dokl. Bolg. Akad. Nauk. (1978) 31; 1131-1134.
Higashino et al., Chem. Pharm. Bull. (1979) 27, 2431.
Higashino et al., Chem. Pharm. Bull. (1979) 27, 3176.
Higashino et al., Fukusokan Kagaku Toronkai Koen Yoshishu, 12th, 1979, 171-5 (Japanese language Conference Report).
Press et al., J. Org. Chem. 48, 4605 (1983).
Schechter et al (1985) J Clin Pharmacol 25, 276.
Higashino et al., Chem Pharm Bull 33, 950 (1985).
Bruns et al., (1986) Mol. Pharmacol. 29: 331-346.
Higashino et al., Chem Pharm Bull 34, 4352 (1986).
Higashino et al., Chem Pharm Bull 34, 4569 (1986).
Molina et al., Tetrahedron Letters (1987) 28, 4451-4454.
Higashino et al., Chem Pharm Bull 35, 4078 (1987).
Jaskolski et al., Acta Crystallogr Sect. C, (1987) C43, 2110-2113.
Molina et al., J. Org. Chem., (1988) 53, 4653-63.
Miyashita et al., Chem Pharm Bull 38, 230(1990).
Hamamichi et al., J. Heterocycl. Chem (1990) 31, 321.
Hamamichi et al., J. Heterocycl. Chem (1990) 27, 835.
Skalski et al., Can. J. Chem (1990) 68, 2164-2170.
Jacobsen et al., J. Med. Chem. (1992) 35(3), 407-423.
Chemical Abstracts, V. 118, No. 3 (1993) Abstract # 22077 Suzuki, Hitomi et al (J. Org. Chem (1993) 58(1) 241-4).
Chemical Abstracts, V. 121, No. 9 (1994) Abstract # 108677 Bouillon et al (Heterocycles (1994) 37(2) 915-32).
Gunderson, Tetrahedron Lett (1994) 35, 3155.
Colotta et al., Eur. J. Jed. Chem. (1995) 30(2), 133-139.
Gundersen et al., Tetrahedron Letters (1995) 36(11), 1945-1948.
Stevenson et al., Tetrahedron Lett. (1996) 37, 8375-8378.
Langli et al., Tetrahedron, vol. 52, Issue 15, Apr. 8, 1996, pp. 5625-5638.
Bertorelli et al (1996) Drug Development Research 37, Issue 2 , pp. 65-72.
Prassad et al., Tetrahedron (1997) 53, 7237-7254.
Chebib et al., Bioorganic & Med. Chem Lett (1997) 5(2) 311-322.
Biraldi et al., J. Med. Chem. (1998) 41, 2126-2133.
Francis et al., J. Med. Chem. (1998) 31, 1014-1020.
Monopoli et al. (1998) J Pharmacol Exp Ther 285 (1): 9.
Kim et al., Arch. Pharmacal. Res. (1998) 21, 458-464.
Molina et al., J. Org. Chem. (1998) 53, 4653-4663.
Suzuki et al., Chem Pharm Bull 46, 199 (1998).
Monopoli et al (1998) NeuroReport 9, 3955-3959.
Strappaghetti et al, Eur. J. Med. Chem (1998) 33, 501-508.
Chorvat et al., J. Med. Chem. (1999) 42(5), 833-848.
Betti et al.,Eur. J. Med Chem(1999) 34(10) 867-875.
Cocuzza et al., Bioorganic & Med. Chem Lett (1999) 9(7) 1063-1066.
Fredholm et al., (1999) Pharmacol Rev. 51, 83-133.
Kopf et al. (1999) Psychopharmacol., 146, 214-219.
Li et al (1999) Experimental Eye Research 68, 9-17.
Svenningsson et al (1999) Progress in Neurobiology 59, 355-396.
Alarcon et al, Tetrahedron Lett (2000) 41, 7211-7215.
Alarcon et al, Bioorg Med Chem Lett (2001) 11, 1855-1858.
Stone et al., (2001) Drug Development Research 52, 323.
Scammell et al., (2001) Neuroscience 107, 653.
El Yacoubi et al., (2001) British Journal of Pharmacology 134, 68-77.
Kase (2001) Bioscience, Biotechnology, and Biochemistry 65, 1447-1457.
Behan et al., (2002) British Journal of Pharmacology (2002) 135, 1435-1442.
Ikeda et al (2002) J Neurochem. 80, 262-70.
Bastia et al., (2002) Neuroscience Letters 328, 241-244.
Hauser et al (2003) Neurology 61 297.
Urade et al (2003) Neurology 2003;61:S94-S96.
Varani et al. (2003) FASEB J. 17, 2148-2150.
Dall'lgna et al., (2003) Br J Pharmacol 138: 1207-1209.
Chase et al., (2003) Neurology 2003;61:S107-S111.
Bara-Jimenez et al., Neurology 2003 61: 293-296.
Bailey et al. J. Neurosci. 22 (21): 9210-9220.

Affiliated with

Also associated with

Rating

A 2a adenosine receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with A 2a adenosine receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and A 2a adenosine receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4235692